Abstract Title:

Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial.

Abstract Source:

Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):440-7. Epub 2007 Jan 26. PMID: 17258897

Abstract Author(s):

Janet Wozniak, Joseph Biederman, Eric Mick, James Waxmonsky, Liisa Hantsoo, Catherine Best, Joanne E Cluette-Brown, Michael Laposata

Article Affiliation:

Pediatric Psychopharmacology Research Unit, Massachusetts General Hospital, Boston, MA 02138, USA. [email protected]

Abstract:

BACKGROUND: To test the effectiveness and safety of omega-3 fatty acids (Omegabrite(R) brand) in the treatment of pediatric bipolar disorder (BPD). METHOD: Subjects (N=20) were outpatients of both sexes, 6 to 17 years of age, with a DSM-IV diagnosis of BPD and Young Mania Rating Scale (YMRS) score of>15 treated over an 8-week period in open-label trial with omega-3 fatty acids 1290 mg-4300 mg combined EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). RESULTS: Subjects experienced a statistically significant but modest 8.9+/-2.9 point reduction in the YMRS scores (baseline YMRS=28.9+/-10.1; endpoint YMRS=19.1+/-2.6, p<0.001). Adverse events were few and mild. Red blood cell membrane levels of EPA and DHA increased in treated subjects. CONCLUSIONS: As only 35% of these subjects had a response by the usual accepted criteria of>50% decrease on the YMRS, omega-3 fatty acids treatment was associated with a very modest improvement in manic symptoms in children with BPD.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.